Michael Schmidt analyst GUGGENHEIM

Currently out of the existing stock ratings of Michael Schmidt, 113 are a BUY (75.33%), 37 are a HOLD (24.67%).

Michael Schmidt

Work Performance Price Targets & Ratings Chart

Analyst Michael Schmidt, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 61.97% that have a potential upside of 43.3% achieved within 311 days.

Michael Schmidt’s has documented 327 price targets and ratings displayed on 41 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ARVN, Arvinas at 12-Dec-2024.

Wall Street Analyst Michael Schmidt

Analyst best performing recommendations are on IONS (IONIS PHARMACEUTICALS).
The best stock recommendation documented was for IONS (IONIS PHARMACEUTICALS) at 7/14/2016. The price target of $26 was fulfilled within 1 day with a profit of $1.48 (6.04%) receiving and performance score of 60.36.

Average potential price target upside

CLVS Clovis Oncology EXEL Exelixis FPRX Five Prime Therapeutics IMMU Immunomedics IMRX Immuneering Corp MRTX Mirati Ther RLAY Relay Therapeutics  AGIO Agios Pharm BLUE Bluebird bio BPMC Blueprint Medicines Corp DRNA Dicerna Pharmaceuticals IMGN ImmunoGen INCY yte FATE Fate Therapeutics GMAB Genmab AS IONS Ionis Pharmaceuticals ORIC Oric Pharmaceuticals  PBYI Puma Biotechnology RAIN Rain Therapeutics ACET Adicet Bio RUBY Rubius Therapeutics TPTX Turning Point Therapeutics XNCR Xencor SGEN Seagen ALKS Alkermes Plc ALNY Alnylam Pharmaceuticals ZNTL Zentalis Pharmaceuticals Llc BGNE BeiGene Ltd DCPH Deciphera Pharmaceuticals LLC AFMD Affimed NV ALLO Allogene Therapeutics ARVN Arvinas ERAS Erasca NLTX Neoleukin Therapeutics NTLA Intellia Therapeutics RVMD Revolution Medicines ADAP Adaptimmune Therapeutics Plc MRSN Mersana Therapeutics SNDX Syndax Pharmaceuticals QURE Uniqure NV IMCR Immunocore Holdings Ltd

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

2 years 6 months 10 days ago
(14-Jun-2022)

0/10 (0%)

$4.56 (102.70%)

Hold

$4.75

$4.66 (5177.78%)

$5.75

3 years 1 months 21 days ago
(03-Nov-2021)

10/12 (83.33%)

$0.06 (1.28%)

65

Sell

4 years 1 months 18 days ago
(06-Nov-2020)

3/5 (60%)

$5.73 (134.19%)

42

Buy

$16

$15.91 (17677.78%)

$17

4 years 4 months 17 days ago
(07-Aug-2020)

5/12 (41.67%)

$10.58 (195.20%)

77

Sell

$4

$3.91 (4344.44%)

$3

4 years 7 months 18 days ago
(06-May-2020)

3/5 (60%)

$-4.07 (-50.43%)

191

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Michael Schmidt is most bullish on?

Potential upside of $23.16 has been obtained for INCY (YTE)

Which stock is Michael Schmidt is most reserved on?

Potential downside of -$0.29 has been obtained for EXEL (EXELIXIS)

What Year was the first public recommendation made by Michael Schmidt?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?